Acute and chronic hemodynamic changes after propranolol in patients with cirrhosis under primary and secondary prophylaxis of variceal bleeding: A pilot study

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 5, 2010, Pages 507-512

  De Madaria, Enrique ^a   Palazón, José María ^a,f   Hernández, Flavia Tamara ^b   Sánchez Paya, José ^c   Zapater, Pedro ^b,f   Irurzun, Javier ^d   De España, Francisco ^d   Pascual, Sonia ^a,f   Such, José ^a,f   Sempere, Laura ^a   Carnicer, Fernando ^a,f   García Herola, Antonio ^e   Valverde, Jaime ^e   Pérez Mateo, Miguel ^a,f  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b Servei Farmacologia Clínica   (Spain)

^c Medicina Preventiva ^*  (Spain)

^d UNIVERSITY OF ALICANTE   (Spain)

^e Marina Baixa Hospital   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Hepatic venous pressure gradient; Hypertension; Portal; Propranolol; Variceal bleeding

Indexed keywords

PROPRANOLOL;

ADULT; ARTICLE; BAND LIGATION; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ESOPHAGUS VARICES; FEMALE; HEART RATE; HEMODYNAMICS; HEPATIC VENOUS PRESSURE GRADIENT; HUMAN; HUMAN TISSUE; IMPOTENCE; LIGATION; LIVER CIRCULATION; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; PILOT STUDY; PREDICTION AND FORECASTING; PRESSURE GRADIENT; PRESSURE MEASUREMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY PREVENTION; TITRIMETRY; TREATMENT OUTCOME; VARIX BLEEDING; VENOUS PRESSURE;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROPRANOLOL; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS PRESSURE;

EID: 77951259374     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832ca06b     Document Type: Article

References (36)

1. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80:800-809.
2. Burroughs AK. The natural history of varices. J Hepatol 1993; 17 (Suppl 2):S10-S13.
3. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997; 92:1081-1091.
4. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med 2001; 345:669-681.
5. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346:1056-1059.
6. Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334:1624-1629.
7. Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345:647-655.
8. McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N, Burroughs AK. Clinical vs haemodynamic response to drugs in portal hypertension. J Hepatol 1998; 28:1015-1019.
9. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32:930-934.
10. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99:1401-1407.
11. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131:1611-1624.
12. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37:902-908.
13. Villanueva C, Lopez-Balaguer JM, Aracil C, Kolle L, Gonzalez B, Minana J, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004; 40:757-765.
14. De Franchis R, Primignani M. Why do varices bleed? Gastroenterol Clin North Am 1992; 21:85-101
15. Patch D, Sabin CA, Goulis J, Gerunda G, Greenslade L, Merkel C, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123:1013-1019.
16. Thalheimer U, Mela M, Patch D, Burroughs AK. Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence. Gut 2004; 53:143-148.
17. Thalheimer U, Mela M, Patch D, Burroughs AK. Targeting portal pressure measurements: a critical reappraisal. Hepatology 2004; 39:286-290.
18. Paquet KJ, Oberhammer E. Sclerotherapy of bleeding oesophageal varices by means of endoscopy. Endoscopy 1978; 10:7-12.
19. Groszmann RJ,Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39:280-282.
20. Feu F, Bordas JM, Luca A, Garcia-Pagan JC, Escorsell A, Bosch J, et al. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology 1993; 18:1082-1089.
21. Luca A, Garcia-Pagan JC, Feu F, Lopez-Talavera JC, Fernandez M, Bru C, et al. Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology 1995; 21:83-88.
22. Albillos A, Perez-Paramo M, Cacho G, Iborra J, Calleja JL, Millan I, et al. Accuracy of portal and forearm blood flow measurements in the assessment of the portal pressure response to propranolol. J Hepatol 1997; 27:496-504.
23. Valla D, Bercoff E, Menu Y, Bataille C, Lebrec D. Discrepancy between wedged hepatic venous pressure and portal venous pressure after acute propranolol administration in patients with alcoholic cirrhosis. Gastroenterology 1984; 86:1400-1403.
24. Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6:101-106.
25. De Franchis R. Portal hypertension II. Proceedings of the Second International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies. Oxford: Blackwell Science Ltd.; 1996.
26. Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7:648-653.
27. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. Aliment Pharmacol Ther 2005; 22:433-439.
28. De BK, Das D, Sen S, Biswas PK, Mandal SK, Majumdar D, et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002; 17:183-189.
29. De BK, Sen S, Biswas PK, Sengupta D, Biswas J, Santra A, et al. Propranolol in primary and secondary prophylaxis of variceal bleeding among cirrhotics in India: a hemodynamic evaluation. Am J Gastroenterol 2000; 95:2023-2028.
30. Routledge PA, Shand DG. Clinical pharmacokinetics of propranolol. Clin Pharmacokinet 1979; 4:73-90.
31. Wood AJ, Carr K, Vestal RE, Belcher S, Wilkinson GR, Shand DG. Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol 1978; 6:345-350.
32. Lalonde RL, Pieper JA, Straka RJ, Bottorff MB, Mirvis DM. Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state. Eur J Clin Pharmacol 1987; 33:315-318.
33. Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange K, et al. A La Carte treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002; 36:1361-1366.
34. Escorsell A, Bordas JM, Castaneda B, Llach J, Garcia-Pagan JC, Rodes J, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31:1061-1067.
35. Avgerinos A, Armonis A, Stefanidis G, Mathou N, Vlachogiannakos J, Kougioumtzian A, et al. Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology 2004; 39:1623-1630.
36. Pereira-Lima JC, Zanette M, Lopes CV, de Mattos AA. The influence of endoscopic variceal ligation on the portal pressure gradient in cirrhotics. Hepatogastroenterology 2003; 50:102-106.